Cargando…

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals

BACKGROUND AND AIM: This study is an evaluation of liver fibrosis measurements determined using transient elastography and aspartate aminotransferase-to-platelet ratio index (APRI) scores of patients diagnosed with chronic hepatitis C (CHC) who were treated with direct-acting antivirals (DAAs). MATE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tufan, Ayse Gokcen, Hakim, Gozde Dervis, Akar, Harun, Akarsu, Mesut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349343/ https://www.ncbi.nlm.nih.gov/pubmed/35949443 http://dx.doi.org/10.14744/hf.2020.2020.0002

Ejemplares similares

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Which is the best choice for Helicobacter pylori eradication? Dual therapy or quadruple therapy?
por: Bacaksız, Elif Gram, et al.
Publicado: (2022)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Hepatitis C Virus-associated Membranoproliferative Glomerulonephritis Treated with Directly Acting Antiviral Therapy
por: Nayak, S., et al.
Publicado: (2018)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
por: Fayed, Hanan Mahmoud, et al.
Publicado: (2020)

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
por: Lee, Sun Hee, et al.
Publicado: (2020)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
por: Iliescu, Elena Laura, et al.
Publicado: (2020)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Evaluation of colon mucosa using screening colonoscopy and flexible spectral imaging color enhancement in patients with long lasting ulcerative colitis
por: Akkaya Özdi̇nç, Seda, et al.
Publicado: (2021)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
por: Pan, Jason J., et al.
Publicado: (2018)

Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
por: Ko, Yi-Ling, et al.
Publicado: (2018)

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
por: Rodríguez-Osorio, Iria, et al.
Publicado: (2019)

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
por: Chae, Hee Bok, et al.
Publicado: (2013)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C
por: Sherigar, Jagannath M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9ieq0ebvop4ercs5np0dkoqt4g